How Has The Non-Alcoholic Steatohepatitis Biomarkers Market Size Evolved In Recent Years?
The non-alcoholic steatohepatitis biomarkers market has seen considerable growth due to a variety of factors.
• The market size for biomarkers of non-alcoholic steatohepatitis has seen an extraordinary surge in recent years. The projected growth is from $1.36 billion in 2024 to $1.7 billion in 2025, displaying a compound annual growth rate (CAGR) of 24.8%. Factors that contribute to this growth in the previous period include diabetes and metabolic syndrome, increased awareness and screening initiatives, limitations of liver biopsy, regulatory endorsements, a shift towards individualised medicine, and clinical trials for NASH.
What are the Market Size and Expected Growth Rates for the Non-Alcoholic Steatohepatitis Biomarkers Market Size In The Coming Years?
The Non-Alcoholic Steatohepatitis Biomarkers market is expected to maintain its strong growth trajectory in upcoming years.
• The market for non-alcoholic steatohepatitis biomarkers is predicted to experience significant growth in the coming years. It is projected to expand to $3.86 billion by 2029, with an impressive compound annual growth rate (CAGR) of 22.8%.
Various factors are driving this predicted growth during the forecast period, including the development of new therapies, the advancement of precision medicine, patient advocacy efforts, the incorporation of multi-omics data, and improved patient engagement. Key trends during this period are anticipated to be telemedicine and remote patient monitoring, groundbreaking diagnostic platforms, international research collaborations, advancements in technology for biomarker discovery, the integration of artificial intelligence (AI), and the inclusion of imaging biomarkers.
Which Key Drivers Are Propelling The Non Alcoholic Steatohepatitis Biomarkers Market's Growth?
The rise in liver cancer cases is anticipated to spur the expansion of the non-alcoholic steatohepatitis biomarkers market. This type of cancer indicates the formation of malignant tumors within the liver, either originating from the liver itself (primary liver cancer) or metastasizing to the liver from different parts of the body (secondary or metastatic liver cancer). Biomarkers for Non-alcoholic steatohepatitis (NASH) are employed in diagnosing liver cancer early, tracking disease progression, and evaluating treatment responses. They also offer prognostic data and can minimize the necessity for invasive procedures. For example, the World Cancer Research Fund, a non-profit organization based in the UK, reported approximately 866,136 new liver cancer cases worldwide in 2022, making it the 6th most prevalent cancer globally. Consequently, this increase in liver cancer prevalence is propelling the expansion of the non-alcoholic steatohepatitis biomarkers market.
What Are The Key Segments Within The Global Non Alcoholic Steatohepatitis Biomarkers Market?
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-
4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
Pre-Book The Non Alcoholic Steatohepatitis Biomarkers Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Non Alcoholic Steatohepatitis Biomarkers Market?
Innovations in technology are becoming a significant trend in boosting the non-alcoholic steatohepatitis biomarkers market's popularity. To consolidate their market position, leading companies focus on creating unique solutions. For instance, in October 2022, an exclusive five-year licensing agreement was struck between GENFIT, a biopharmaceutical company based in France, and LabCorp, a life sciences firm from the US, for GENFIT's NIS4 technology. This technology is a transformative, multi-biomarker algorithm designed specifically to detect non-alcoholic steatohepatitis (NASH) in patients, and those with significant to advanced fibrosis (F > 2), also known as at-risk NASH. LabCorp, as part of this deal, will develop a blood-based molecular diagnostic test using NIS4 technology in the US and Canada to provide healthcare professionals with widespread access.
Who Are the Key Players In The Non Alcoholic Steatohepatitis Biomarkers Market?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market include:
• Genfit SA
• Prometheus Laboratories Inc.
• Siemens Medical Solutions USA Inc.
• BioPredictive
• Quest Diagnostics
• AstraZeneca Plc.
• Laboratory Corporation of America Holdings
• Pfizer Inc.
• Bristol-Myers Squibb Company
• NGM Biopharmaceuticals Inc.
• Gilead Sciences Inc.
• Perspectum Diagnostics Ltd.
• One Way Liver SL
• Enterome SA
• Echosens SA
• Cisbio Bioassays SAS
• Celerion Inc.
• Boehringer Ingelheim GmbH Inc.
• Exalenz Bioscience Ltd.
• Novartis AG
• Novo Nordisk A/S
• Allergan PLC.
• Glympse Bio
• HistoIndex Pte Ltd
• Cirius Therapeutics
• Intercept Pharmaceuticals
• Viking Therapeutics
• Madrigal Pharmaceuticals
• Galmed Pharmaceuticals
• Immuron Ltd
• Metacrine
What Are The Regional Insights Into The Non Alcoholic Steatohepatitis Biomarkers Market?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
